Thalys(603716)

Search documents
塞力医疗(603716) - 2025年第五次临时股东会决议公告
2025-10-09 11:00
证券代码:603716 证券简称:塞力医疗 公告编号:2025-088 塞力斯医疗科技集团股份有限公司 2025年第五次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 本次会议是否有否决议案:无 一、 会议召开和出席情况 (一)股东会召开的时间:2025 年 10 月 9 日 (二)股东会召开的地点:公司(武汉市东西湖区金山大道 1310 号)A 栋 A 会议室 | 1、出席会议的股东和代理人人数 | 1,312 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数(股) | 9,206,659 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例(%) | 4.4651 | (四)表决方式是否符合《公司法》及《公司章程》的规定,股东会主持情况等。 本次股东会由塞力斯医疗科技集团股份有限公司董事会召集,由公司董事 长温伟先生主持。本次会议的召集、召开、表决方式符合有关法律、行政法规、 部门规章和《公司章程》的有关规定。 (五)公司董事 ...
医药商业板块10月9日涨0.56%,塞力医疗领涨,主力资金净流入239.97万元
Zheng Xing Xing Ye Ri Bao· 2025-10-09 09:03
| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301015 | 百洋医药 | 27.17 | -2.96% | 5.74万 | 1.58亿 | | 301584 | C建发致 | 28.15 | -2.90% | 21.71万 | 6.15亿 | | 600833 | 第一医药 | 13.38 | -2.76% | 8.11万 | 260'T | | 301126 | 达嘉维康 | 11.13 | -2.37% | 4.04万 | 4537.69万 | | 603108 | 润达医疗 | 15.70 | -1.88% | 19.17万 | 3.00亿 | | 000705 | 浙江震元 | 9.78 | -1.41% | 13.46万 | 1.31亿 | | 002462 | 章章点 | 13.69 | -0.58% | 4.41万 | 6013.33万 | | 300937 | 药易购 | 26.53 | -0.49% | 1.29万 | 3415.25万 | | 600538 | 国发股份 ...
晚间公告丨9月30日这些公告有看头
第一财经· 2025-09-30 14:42
Group 1 - Cambrian's private placement price is set at 1195.02 yuan per share, with a total fundraising amount of 3.985 billion yuan [4] - Bee Assistant plans to raise no more than 984 million yuan for projects including cloud terminal computing power center and IoT terminal upgrades [5] - Kexing Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange [6] - Three squirrels have received approval from the China Securities Regulatory Commission for H-share issuance, with plans to issue up to 81.5483 million shares [7] - Ruiming Technology has submitted an application for H-share issuance to the Hong Kong Stock Exchange [8] Group 2 - Binhua Co. plans to invest 1.421 billion yuan in an integrated project for wind, solar, and energy storage [9] - Sains plans to invest no more than 300 million yuan in the expansion of its selection agent project [10] Group 3 - Hunan YN reports no significant changes in its internal and external operating environment [11] - Electric Power Investment has had its major asset replacement review suspended by the Shenzhen Stock Exchange due to expired financial documents [12] - Guanzhong Ecological is in the planning stage for acquiring a 51% stake in Hangzhou Actuary [13][14] Group 4 - Aima Technology's subsidiary is transferring production capacity and ceasing operations due to strategic adjustments [17] - Fosun Pharma's subsidiary has received approval for clinical trials of a new drug [18] - SAIC Group's subsidiary plans to invest 666 million yuan in the restructuring of SAIC Hongyan [19] Group 5 - Hanwei Technology plans to sell 65% of Hanwei Zhiyuan for approximately 440 million yuan [20] - Xingtong Co. has been awarded new capacity for coastal inter-provincial bulk liquid hazardous goods transportation [21][22] Group 6 - EVE Battery Investment received a cash dividend of 375 million HKD from its associate company [23] - Shanmei International's chairman has resigned due to work changes [24] - Weiye Co.'s chairman has resigned for personal reasons [25] Group 7 - Jiao Da Sino's chairman has been placed under detention [26] - Duorui Pharmaceutical is planning a change in control, leading to a stock suspension [27][28] - *ST Zhengping's stock has been suspended for investigation due to abnormal price fluctuations [29] Group 8 - Zhenray Technology's chairman has had detention measures lifted [30] - Shiming Technology's chairman has had detention measures changed to a warning [31] - Nanxin Pharmaceutical is under investigation by the CSRC for suspected violations in annual report disclosures [32] Group 9 - Daqian Ecology's shareholder plans to reduce holdings by up to 3% [33] - Rundar Medical's shareholders plan to reduce holdings by up to 2.99% [34][35] - Saili Medical's shareholder plans to reduce holdings by up to 2% [36] Group 10 - Huaxin Environmental plans to repurchase shares for 40 to 80 million yuan [37] - Tianyong Intelligent has been awarded a contract worth 58.8 million yuan for an engine assembly line project [38] - Zhongwu Drone has signed a significant contract worth 615 million yuan for drone systems [39]
晚间公告丨9月30日这些公告有看头
Di Yi Cai Jing· 2025-09-30 11:44
Group 1 - Cambrian's private placement price is set at 1195.02 yuan per share, with a total fundraising amount of 3.985 billion yuan [2] - Bee Assistant plans to raise up to 984 million yuan for projects including cloud terminal computing power center and IoT terminal upgrades [3] - Kexing Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange [4] Group 2 - Three squirrels received approval from the China Securities Regulatory Commission for H-share issuance, planning to issue up to 81.5483 million shares [5] - Ruiming Technology has submitted an application for H-share issuance to the Hong Kong Stock Exchange [6] - Binhua Co. plans to invest 1.421 billion yuan in an integrated project for wind and solar energy [7] Group 3 - Sainz's subsidiary plans to invest up to 300 million yuan in the expansion of selection and extraction agents [8] - Hunan YN reported no significant changes in its internal and external operating environment [9] - Electric Power Investment plans to restructure assets and has received a notice from the Shenzhen Stock Exchange to suspend review [10] Group 4 - Guanzhong Ecology is in the planning stage to acquire 51% of Hangzhou Actuary [11] - Aima Technology announced the transfer and suspension of production capacity at its subsidiary in Guangdong [12] - Fosun Pharma's subsidiary received approval for clinical trials of a new drug [13] Group 5 - EVE Battery Investment received a cash dividend of 375 million HKD from its indirect associate, Simoer International [14] - Shanmei International announced a change in its board leadership due to personnel changes [15] - Weiye Co. announced the resignation of its chairman for personal reasons [16] Group 6 - Jiaoda Sinuo's chairman is under detention, and the company has appointed a new acting chairman [17] - Duorui Pharmaceutical is planning a change in control, leading to a stock suspension [18] - ST Zhengping's stock price has seen an abnormal increase, leading to a suspension for investigation [19] Group 7 - Daqian Ecology's shareholder plans to reduce its stake by up to 3% [20] - Rundat Medical's shareholders plan to collectively reduce their stake by up to 2.99% [21] - Seli Medical's shareholder plans to reduce its stake by up to 2% [22] Group 8 - Tianyong Intelligent has been awarded a contract worth 58.8 million yuan for an engine assembly line project [23] - Zhongwu Drone signed a significant contract worth 615 million yuan for drone systems [24]
塞力医疗(603716) - 关于持股5%以上股东减持股份计划公告
2025-09-30 09:36
| 证券代码:603716 | 证券简称:塞力医疗 | 公告编号:2025-087 | | --- | --- | --- | | 债券代码:113601 | 债券简称:塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 持股 5%以上股东的基本情况 截至本公告披露日,上海盎泽私募基金管理有限公司-盎泽太盈六号私募证 券投资基金(以下简称"上海盎泽")持有塞力斯医疗科技集团股份有限公司(以 下简称"公司")12,100,399 股无限售条件流通股,占公司总股本的 5.76%(因 可转债转股导致公司总股本增加,上海盎泽的持股比例相应发生变动:截至 2025 年 6 月 30 日,公司总股本为 191,018,075 股,上海盎泽彼时持股比例为 6.33%; 截至 2025 年 8 月 20 日,公司总股本增至 210,139,246 股,上海盎泽持股比例随 之变为 5.76%。本次相关计算以截至 2025 年 8 月 ...
塞力医疗:持股5%以上股东上海盎泽拟减持不超2%公司股份
Xin Lang Cai Jing· 2025-09-30 09:23
Core Viewpoint - The major shareholder of Saily Medical, Shanghai Angze Private Fund Management Co., Ltd., plans to reduce its stake in the company by up to 4.2028 million shares, representing no more than 2% of the total share capital, due to its own investment planning arrangements [1] Summary by Categories Shareholder Actions - The reduction of shares will occur between October 30, 2025, and January 29, 2026 [1] - The shares will be sold through centralized bidding and block trading methods, with a maximum of 2.1014 million shares to be sold via each method [1] Financial Implications - The planned reduction does not set a price range for the shares being sold [1]
塞力医疗(603716.SH):上海盎泽拟减持不超2%股份
Ge Long Hui A P P· 2025-09-30 09:23
格隆汇9月30日丨塞力医疗(维权)(603716.SH)公布,上海盎泽根据自身投资规划安排,计划于本公告 披露日起15个交易日后的三个月(即2025年10月30日至2026年1月29日),通过集中竞价、大宗交易方 式减持不超过所持公司股份420.28万股,占公司总股本的2%(若减持期间发生送股、资本公积金转增 股本、可转债转股等导致股本变动事项的,拟减持的比例不变,减持数量将根据公司总股本的变动进行 相应调整)。 ...
塞力医疗:股东拟减持不超2%公司股份
Zheng Quan Shi Bao Wang· 2025-09-30 09:19
人民财讯9月30日电,塞力医疗(603716)9月30日公告,持股5.76%的股东上海盎泽私募基金管理有限 公司-盎泽太盈六号私募证券投资基金计划通过集中竞价、大宗交易方式减持不超过所持公司股份 420.28万股,占公司总股本的2%。 ...
医药商业板块9月30日跌0.11%,C建发致领跌,主力资金净流出2.39亿元
Zheng Xing Xing Ye Ri Bao· 2025-09-30 08:44
Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.11% on September 30, with C Jianfa leading the drop [1] - The Shanghai Composite Index closed at 3882.78, up 0.52%, while the Shenzhen Component Index closed at 13526.51, up 0.35% [1] Stock Performance - Notable gainers in the pharmaceutical sector included: - Baiyang Pharmaceutical (301015) with a closing price of 28.00, up 1.93% [1] - Saily Medical (603716) at 24.87, up 1.84% [1] - Guofa Co., Ltd. (600538) at 5.63, up 1.26% [1] - C Jianfa (301584) was the biggest loser, closing at 28.99, down 15.04% with a trading volume of 264,700 shares and a turnover of 817 million [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 239 million in main funds, while retail investors contributed a net inflow of 219 million [2][3] - The main funds showed varying net inflows and outflows across different stocks, with Saily Medical experiencing a net inflow of approximately 889,790 and Baiyang Pharmaceutical seeing a net inflow of 738,150 [3]
塞力医疗股价涨5.04%,财通基金旗下1只基金位居十大流通股东,持有64.34万股浮盈赚取79.14万元
Xin Lang Cai Jing· 2025-09-30 03:18
Group 1 - The core point of the news is that Selys Medical experienced a stock price increase of 5.04%, reaching 25.65 CNY per share, with a trading volume of 267 million CNY and a turnover rate of 5.12%, resulting in a total market capitalization of 5.39 billion CNY [1] - Selys Medical Technology Group Co., Ltd. is located in Wuhan, Hubei Province, and was established on February 23, 2004, with its listing date on October 31, 2016. The company's main business involves centralized marketing and service for medical testing, as well as the agency and independent research, production, and sales of in vitro diagnostic products [1] - The revenue composition of Selys Medical includes IVD business at 39.91%, SPD business at 38.01%, and pure sales at 22.08% [1] Group 2 - From the perspective of the top ten circulating shareholders of Selys Medical, data shows that a fund under Caitong Fund ranks among the top ten shareholders. The Caitong Advantage Industry Rotation Mixed A Fund (011201) entered the top ten shareholders in the second quarter, holding 643,400 shares, which accounts for 0.34% of the circulating shares [2] - The Caitong Advantage Industry Rotation Mixed A Fund (011201) was established on February 9, 2021, with a latest scale of 536 million CNY. Year-to-date returns are 19.74%, ranking 4636 out of 8167 in its category; the one-year return is 22.47%, ranking 4803 out of 8010; and since inception, it has a loss of 27.14% [2]